focus -WSS

focus

author：knowledge 2025-10-01 21:33:59 - browse：8

The term “excited delirium” has been used for years by law enforcement and other first responders, including health care workers, to describe people who exhibit behavior that is considered “out of control.” This diagnosis has been applied again and again, even posthumously, as a justification for extreme, and sometimes deadly, interventions by law enforcement. It came up most recently in the trials of two police officers accused of causing the death of Elijah McClain, a Colorado man; both officers were acquitted this week.

But excited delirium is not an evidence-based medical diagnosis. The American College of Emergency Physicians recently withdrew a 2009 white paper endorsing the concept, and California has banned it as a cause of death. Other states may follow suit.

On this week’s episode, we are joined by Utsha G. Khatri, an assistant professor of emergency medicine and population health and policy at the Icahn School of Medicine at Mount Sinai, and emergency physician Brooks Walsh, who was involved with the campaign to get ACEP to withdraw the 2009 white paper. Khatri and Walsh speak about why the “excited delirium” label is both unnecessary and dangerous.

“We recognize that some patients are confused. They’re not thinking clearly they might have risk for becoming violent either toward themselves or towards other staff,” Khatri said. “It is our job not just to keep them and everyone else safe, but also to most importantly find out what is causing them to act in this way.”

You can read Khatri’s First Opinion essay on the end of “excited delirium” here.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Americans' trust in science, scientist continues decline: Report

WSS

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

What PEPFAR has meant on the ground in Ukraine

Pregnancy discrimination could be enabled by AI

Arc Institute generative AI designs new CRISPR systems

Readers respond to H5N1 and livestock movements, and more

STAT letters to the editor on burnt

knowledge

focus

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Patients' immediate access to test results puts radiologists in a bind

After affirmative action ruling, medical educators look to 'holistic review'

Readers respond to H5N1 and livestock movements, and more

FDA approval of Sarepta Duchenne genetic therapy gives me hope

It's time to retire 'poor historian' from clinicians' vocabularies

The high cost of giving birth even with insurance

NVIDIA and Google execs on the future of AI and drug discovery

Tori Bowie and the unacceptable rates of Black maternal death

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

explore

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Americans' trust in science, scientist continues decline: Report

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

After sickle

In diabetes hearing, Sanders takes on a new foe: food makers

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

focus

focus

leisure time

Wikipedia